Wells Fargo’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-181
| Closed | -$2.06K | – | 7837 |
|
|
2023
Q4 | $2.06K | Buy |
181
+90
| +99% | +$707 | ﹤0.01% | 6103 |
|
|
2023
Q3 | $367 | Buy |
91
+4
| +5% | +$30 | ﹤0.01% | 6432 |
|
|
2023
Q2 | $620 | Buy |
87
+2
| +2% | +$14 | ﹤0.01% | 6443 |
|
|
2023
Q1 | $630 | Buy |
85
+31
| +57% | +$261 | ﹤0.01% | 6498 |
|
|
2022
Q4 | $395 | Sell |
54
-50
| -48% | -$421 | ﹤0.01% | 6445 |
|
|
2022
Q3 | $1K | Sell |
104
-1
| -1% | -$19 | ﹤0.01% | 6537 |
|
|
2022
Q2 | $2K | Sell |
105
-567
| -84% | -$14.7K | ﹤0.01% | 6423 |
|
|
2022
Q1 | $33K | Sell |
672
-637
| -49% | -$33K | ﹤0.01% | 5834 |
|
|
2021
Q4 | $99K | Buy |
1,309
+1,218
| +1,338% | +$83.1K | ﹤0.01% | 5646 |
|
|
2021
Q3 | $7K | Sell |
91
-1,197
| -93% | -$120K | ﹤0.01% | 6315 |
|
|
2021
Q2 | $179K | Buy |
1,288
+871
| +209% | +$166K | ﹤0.01% | 5077 |
|
|
2021
Q1 | $87K | Sell |
417
-1,525
| -79% | -$306K | ﹤0.01% | 5549 |
|
|
2020
Q4 | $323K | Sell |
1,942
-570
| -23% | -$88.1K | ﹤0.01% | 4830 |
|
|
2020
Q3 | $427K | Buy |
2,512
+46
| +2% | +$6.63K | ﹤0.01% | 4468 |
|
|
2020
Q2 | $409K | Buy |
2,466
+289
| +13% | +$45.1K | ﹤0.01% | 4474 |
|
|
2020
Q1 | $252K | Buy |
2,177
+896
| +70% | +$126K | ﹤0.01% | 4532 |
|
|
2019
Q4 | $189K | Buy |
1,281
+507
| +66% | +$76.9K | ﹤0.01% | 4990 |
|
|
2019
Q3 | $106K | Buy |
774
+50
| +7% | +$7.03K | ﹤0.01% | 5298 |
|
|
2019
Q2 | $94K | Buy |
+724
| New | +$84.1K | ﹤0.01% | 5333 |
|
Wells Fargo's HARP Position: Q1 2024 in Review
Wells Fargo sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2024, closing a stake of 181 shares — an estimated $2.06K sold.
Wells Fargo first reported a position in HARP in Q2 2019 and held it in 19 quarters. The position peaked at $427K in Q3 2020. 0 funds tracked by Wall St. Rank hold HARP as of Q1 2024.
- Wells Fargo reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Wells Fargo sold 181 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $2.06K.
- Wells Fargo first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q2 2019 and held it in 19 quarters.
- Wells Fargo's Harpoon Therapeutics, Inc. Common Stock position peaked at $427K in Q3 2020.
- 0 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Wells Fargo's 13F filing for Q1 2024, filed 10 May 2024.